Abstract 2053P
Background
In recent decades, the home care initiative has expanded in the health system, mainly linked to hospitals. The mismatch between available financial resources and advances related to cancer therapy requires projects to improve cost minimization processes.
Methods
The variables collected for each sector were described through monthly totals and averages per year. To verify the existence of an association between expenses with material, medication and chemotherapy and the cost avoided with monthly dehospitalization, Pearson's correlation coefficients and their respective p-values were calculated. Spending on medication and total spending on material, medication and chemotherapy were related to the amount avoided using linear regression models, in order to estimate the effect of increased spending on medication on avoided costs. The same procedure was performed to estimate the effect of increased costs on bed turnover, using linear regressions, and on the number of days of hospitalization avoided per month, using Poisson regression.
Results
Pearson's coefficients confirm a relationship, with a positive sign, between expenses and avoided costs with early dehospitalization, showing a perfect positive relationship between the variables, with a statistically significant p-value. Effect of expenses on total costs with hospitalization avoided on General Hospitalization, Coefficients - Amount spent on medication:100.36; 95% CI (14.26, 186.45); p-value= 0.02. By the linear model, the total avoided cost with discharges was $795,204.52 in the three-year period from 2020 to 2022, for a total of 3,722 avoided hospitalization days and an average cost avoided with discharges of $70,146.06. Effect of expenses on the days of hospitalization avoided (Poisson regression) was statistically significant in all variables (p-value<0.001).
Conclusions
All tests - Pearson Correlation coefficients, Poisson regression, and Generalized Linear Model (p<0.05) confirmed the hypothesis that the discharge managing with outpatient drug release has a significant effect on the final cost avoided with cancer hospitalization.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2116P - Preoperative body mass index, waist circumference, and mortality after major cancer surgery: A nationwide cohort study in South Korea
Presenter: Jiwon Yoon
Session: Poster session 06
2117P - Dietary patterns and clinical outcomes in patients with lung cancer: What needs to change
Presenter: Imanuely Borchardt
Session: Poster session 06
2118P - Refeeding syndrome: A prospective analysis in adults admitted to an oncology hospital
Presenter: Filipe Gonçalves
Session: Poster session 06
2119P - The prognostic impact of nutritional assessment and scores in advanced gastric cancer
Presenter: Sara Torresan
Session: Poster session 06
2120P - Nutritional deficiency post gastric cancer surgery
Presenter: Abay Makishev
Session: Poster session 06
2121P - Association between nutritional status and adverse events in gastrointestinal cancer patients undergoing outpatient chemotherapy in Japan
Presenter: Naoko Sato
Session: Poster session 06
2122P - Clinical significance of oncology patients’ nutritional status assessment
Presenter: Efthymios Kostaridis
Session: Poster session 06
2123P - Value of immuno-nutritional scores in the prognosis of hospitalised patients with lung cancer
Presenter: Jesús López
Session: Poster session 06
2124P - The impact of NUTRItional status at first medical oncology visit ON Clinical Outcomes: The NUTRIONCO study
Presenter: Maurizio Muscaritoli
Session: Poster session 06
2125P - Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study
Presenter: Alessio Cortellini
Session: Poster session 06